Immunotherapy and evolving approaches for basal cell carcinoma
touchPANEL DISCUSSION for touchONCOLOGY
Listen to leading experts discuss evolving treatment options for patients with EGFR-mutant NSCLC, and the rationale for biomarker testing in both early-stage and metastatic disease to determine best treatment approaches, taking in recently presented data from the World Lung Cancer Congress and ESMO Congress 2021.
The experts
Dr Pasi Jӓnne, Dana-Farber Cancer Institute, Boston, MA, USA
Dr Thanyanan Reungwetwattana, Ramathibodi Hospital, Bangkok, Thailand
Dr Neal Navani, University College London, London, UK
This touchPODCAST is for HCPs only.
This…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.